Marek HealthMarek HealthMarek Health
Log inStart treatment online

Dapagliflozin

Oral tablet (5mg, 10mg)

Marketing purposes only. Actual medications, if prescribed, are dispensed by a licensed pharmacy.

weight

DapagliflozinDapagliflozin

SGLT2 inhibitor (Farxiga) with FDA approvals spanning type 2 diabetes, heart failure, and chronic kidney disease. Provides cardiorenal protection beyond glycemic control via caloric restriction-mimetic mechanisms, AMPK activation, ketone production, and reduced oxidative stress.

HbA1c reduction 0.5 to 0.8%

Weight loss 2 to 3 kg

BP reduction ~3 to 5 mmHg

Proven HF + CKD outcome benefits (DAPA-HF, DAPA-CKD)

No commitment · HSA/FSA eligibleNo commitment · HSA/FSA eligible

How it works

Mechanism of action

Inhibits SGLT2 in the proximal renal tubule, the transporter responsible for ~90% of filtered glucose reabsorption. Produces glucosuria, osmotic diuresis, and caloric deficit mimicking metabolic effects of caloric restriction.

The baseline panel.

Every Marek client receives this baseline panel before a provider review. Your provider may add additional biomarkers based on your health history, symptoms, and goals, pulling from 1,000+ available markers. See more biomarkers →

Hormone Profile

12 markers

Sex hormones

  • Total TestosteroneLC/MS
  • Free TestosteroneEquilibrium Dialysis
  • Estradiol, Sensitive / UltrasensitiveLC/MS
  • Sex Hormone Binding Globulin (SHBG)
  • ProgesteroneLC/MSFemale panel
  • Prolactin
  • Luteinizing Hormone (LH)
  • Follicle-Stimulating Hormone (FSH)
  • hCG, Total, QuantitativeFemale panel, pre-menopause

Adrenals & neurosteroids

  • Cortisol
  • DHEA-S

Growth hormone / IGF-1

  • Insulin-Like Growth Factor I (IGF-1)

Thyroid Status

3 markers

Thyroid hormones

  • Thyroid Stimulating Hormone (TSH)
  • Free T4
  • Free T3

Heart Health

9 markers

Cardiovascular health

  • Total Cholesterol
  • HDL Cholesterol
  • LDL Cholesterol
  • LDL:HDL Ratio
  • VLDL Cholesterol
  • Triglycerides
  • Apolipoprotein-B (ApoB)
  • C-Reactive Protein, High Sensitivity (hsCRP)
  • Lipoprotein(a) (Lp(a))

Metabolism

3 markers

Insulin sensitivity

  • Blood Glucose
  • Fasting Insulin
  • HbA1c

Organ Function

26 markers

Liver & pancreas

  • AST
  • ALT
  • Bilirubin, Total
  • γ-Glutamyl Transferase (GGT)

Kidney function

  • BUN
  • Creatinine w/ eGFR

Comprehensive Metabolic Panel (CMP)

  • Glucose
  • Blood Urea Nitrogen (BUN)
  • Creatinine
  • eGFR
  • BUN/Creatinine Ratio
  • Sodium
  • Potassium
  • Chloride
  • Carbon Dioxide, Total
  • Calcium
  • Protein, Total
  • Albumin
  • Globulin, Total
  • Albumin/Globulin (A/G) Ratio
  • Alkaline Phosphatase (ALP)
  • AST
  • ALT

Prostate health

  • Prostate-Specific Antigen (PSA)Male panel
  • Free PSAMale panel
  • % Free PSAMale panel

Nutrient Status

31 markers

Vitamins & minerals

  • Vitamin D, 25-OHD (25-Hydroxy)
  • Magnesium, RBC

Iron status

  • Iron
  • Iron Saturation
  • TIBC
  • UIBC
  • Ferritin

Complete Blood Count (CBC)

  • White Blood Count (WBC)
  • Red Blood Count (RBC)
  • Hemoglobin (Hgb)
  • Hematocrit (HCT)
  • MCV
  • MCH
  • MCHC
  • Red Cell Distribution Width (RDW)
  • Platelets
  • Neutrophils
  • Neutrophils (Absolute)
  • Lymphocytes
  • Lymphocytes (Absolute)
  • Neutrophil/Lymphocyte Ratio
  • Monocytes
  • Monocytes (Absolute)
  • Eosinophils
  • Eosinophils (Absolute)
  • Basophils
  • Basophils (Absolute)
  • Immature Cells
  • Immature Granulocytes
  • Immature Granulocytes (Absolute)
  • NRBC, w/ Reflex for Immature Cells

Clinical evidence

The research behind Dapagliflozin.

DAPA-HF: Dapagliflozin in heart failure with reduced ejection fraction

New England Journal of Medicine (2019)

Dapagliflozin reduced worsening heart failure or cardiovascular death by 26% vs placebo in 4,744 patients, more than half of whom did not have diabetes.

Safety profile

Monitoring & safety information.

Commonly reported side effects

  • Genital mycotic (yeast) infections
  • Urinary tract infections
  • Increased urination & thirst

Less common but serious risks

  • Diabetic ketoacidosis (can be euglycemic)
  • Volume depletion & hypotension

Generally not appropriate for

  • On dialysis
  • eGFR <25 at initiation
  • Type 1 diabetes (DKA risk)
  • Active ketoacidosis or recurrent severe UTIs

Typical monitoring

  • HbA1c & renal function
  • Electrolytes & blood pressure
  • Ketones if acutely ill
  • UTI / genital infection symptoms

FAQ

Quick answers.

SGLT2 inhibitor (Farxiga) with FDA approvals spanning type 2 diabetes, heart failure, and chronic kidney disease. Provides cardiorenal protection beyond glycemic control via caloric restriction-mimetic mechanisms, AMPK activation, ketone production, and reduced oxidative stress.
HbA1c reduction 0.5 to 0.8%. Weight loss 2 to 3 kg. BP reduction ~3 to 5 mmHg. Proven HF + CKD outcome benefits (DAPA-HF, DAPA-CKD). Longevity potential via AMPK/ketone effects.
Common side effects include: genital mycotic infections, UTIs, increased urination, thirst. Most side effects are dose-dependent and may resolve with continued use or dose adjustment.
View all FAQs
See all FAQs

SGLT2 inhibitor (Farxiga) with FDA approvals spanning type 2 diabetes, heart failure, and chronic kidney disease. Provides cardiorenal protection beyond glycemic control via caloric restriction-mimetic mechanisms, AMPK activation, ketone production, and reduced oxidative stress.

Treatments are dependent on licensed clinical prescription. Client costs vary based on individual labs and panel in treatments and services.